Nasus Pharma, an Israeli biopharmaceutical company, has said that Taffix, the Company’s new nasal powder inhaler which can block viruses from reaching nasal mucosa, was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.
So the idea here is to basically coat the inner lining of the nose so that a virus will not be able to enter the body that way. Even if this would only give a person temporary protection, such a nasal spray could end any and all pandemic related shutdowns for good.
Think about it: if you can protect yourself from infection without even wearing a mask, no matter how many people crowd together indoors, then the world could go back to business as usual even without a Corona Virus vaccine.
If such a device were available just a few weeks ago then synagogues could have conducted business as usual on Rosh Hashanah and Yom Kipur.
Broadway and all movie theaters could reopen. So could all shopping malls and schools.
“These important results conform with prior in vitro studies performed with Taffix™ that proved its robust activity against the transmission of SARS-CoV-2 ,” said Dr. Dalia Megiddo, Chief Executive Officer of Nasus Pharma.
“This is the first clinical real life data showing that the use of Taffix is highly effective even in the worst-case scenario of a super spread event in the heart of the worst hit city in Israel. Reducing the infection risk by 75% or even 100% can dramatically change the means to fight the worst epidemic humanity have witnessed in close to a 100 years.”
Udi Gilboa, Executive Chairman of the Board of Nasus Pharma added, “This promising clinical data reinforces the potential of Taffix™ to become an important solution and the leading additional layer of protection that will enable the resuming of social and economic activities in a much safer manner.
“With a global challenge to create a new normality while living side by side with the pandemic, we believe Taffix™ can be an important clinically-proven tool offering an additional safety measure to our users and customers. Based on our very encouraging clinical findings, we believe Taffix which is now available globally in many parts of the world, will be used on a daily basis in crowded environment (Tube or Subway, trains, offices, supermarkets, flights, restaurants, etc) and will be key to a personal protection activity as well as part of the public health initiatives to create safer and better protected daily routines.”
Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock.
Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety. Nasus portfolio comprises a number of programs: Intranasal Naloxone (heading to phase 3) and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.